Half of Patients With Newly Diagnosed Vitiligo Do Not Receive Treatment
TUESDAY, Oct. 17, 2023 (HealthDay News) — A high proportion of patients with newly diagnosed vitiligo do not receive any treatment, according to a study recently published in Dermatology and Therapy.David Rosmarin, M.D., from the Indiana University S…
Learn MoreReduced Mortality Risk Seen for Patients With Vitiligo
TUESDAY, Sept. 26, 2023 (HealthDay News) — Patients with vitiligo may have a reduced risk for mortality, according to a study published online Sept. 14 in the Journal of Investigative Dermatology.Hyun Jeong Ju, M.D., Ph.D., from the St. Vincent’s Hos…
Learn MoreIncidence Rate of Diagnosed Vitiligo 22.6 per 100,000 Person-Years
MONDAY, July 24, 2023 (HealthDay News) — Vitiligo diagnosis is more common in older adults and in Hispanic/Latino and Asian American patients, according to a study published online July 19 in JAMA Dermatology.Nicole Mastacouris, from the Donald and B…
Learn MoreAAD: Long-Term Improvement Seen With Ruxolitinib in Vitiligo
TUESDAY, March 28, 2023 (HealthDay News) — For patients with nonsegmental vitiligo, continued improvement was seen during a long-term extension of ruxolitinib treatment, according to a study presented at the annual meeting of the American Academy of …
Learn MoreTopical Cream May Restore Skin Pigmentation in People With Vitiligo
MONDAY, Oct. 24, 2022 (HealthDay News) — For the millions of people who live with vitiligo, a disease that robs the skin of its natural color, a newly approved cream called ruxolitinib (Opzelura) is quickly becoming a game changer.The U.S. Food and D…
Learn MoreRuxolitinib Cream Results in Greater Repigmentation in Vitiligo
THURSDAY, Oct. 20, 2022 (HealthDay News) — For patients with vitiligo, ruxolitinib cream results in greater repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the New England Journal of Medicine….
Learn MoreRuxolitinib Cream Results in Greater Repigmentation in Vitiligo
THURSDAY, Oct. 20, 2022 (HealthDay News) — For patients with vitiligo, ruxolitinib cream results in greater repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the New England Journal of Medicine….
Learn More